Cost-Effectiveness and Budgetary Impact Analysis of High-Dose Quadrivalent Influenza Vaccines for the Elderly Population in Argentina
Author(s)
Espinola N1, Silvestrini Viola C1, Ivalo S2, Bardach A1, Pastori L1
1Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Buenos Aires, Argentina, 2Braulio Moyano Neuropsychiatric Women 's Hospital, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Presentation Documents
OBJECTIVES: Influenza affects millions of people worldwide, particularly older adults. Annual vaccination is the most effective measure to prevent this disease and its complications. This study assessed the cost-effectiveness and budget impact of implementing prophylaxis against the influenza virus using the high-dose quadrivalent influenza vaccine (HD-QIV) in individuals over 65 years of age in Argentina.
METHODS: We conducted a decision tree model from the perspective of social security and the private sector in Argentina, considering a hypothetical cohort of 1 million individuals. The comparators were standard-dose trivalent (SD-TIV) and standard-dose quadrivalent (SD-QIV) influenza vaccines for social security, and SD-QIV for the private sector. Model parameters were collected from official databases, comprehensive literature reviews, and expert consultations. Costs are expressed as USD 2023.
RESULTS: Compared with SD-TIV, the HD-QIV strategy resulted in an ICER of $2,369 with an increase of 0.0014 in quality-adjusted life years (QALYs)/person and an incremental cost of $4.12/person in social security, which is a cost-effective strategy for a cost-effectiveness threshold of $8,241. The HD-QIV strategy is dominant over the SD-QIV strategy for both sectors, gaining 0.0013 QALYs/person and saving $0.17 and $0.77 per person in the social security and private sectors, respectively. Introducing HD-QIV represented an average incremental per-member per-month (PMPM) cost of $0.02 for social security sector, slightly exceeding Argentina's high budget impact threshold ($0.0129 PMPM) estimated. In comparison, the average cost savings for the private sector were estimated at $0.04 PMPM. The PSA showed that the results are robust, and the HD-QIV strategy is cost-effective in 100% of the simulations for both sectors.
CONCLUSIONS: The introduction of HD-QIV in individuals older than 65 years is a cost-effective influenza prevention strategy compared with SD-TIV for social security and dominant compared to SD-QIV for both health sectors in Argentina.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE128
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Thresholds & Opportunity Cost
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines